New hope for tough breast cancer: targeted drug HLX43 enters phase 2 trial
NCT ID NCT07459738
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests a new drug called HLX43 in 60 people with a common type of advanced breast cancer (HR+ HER2-) that has worsened despite standard hormone therapy. The drug is an antibody-drug conjugate that targets PD-L1 to deliver chemotherapy directly to cancer cells. The goal is to see if it can shrink tumors or slow cancer growth.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HORMONE RECEPTOR POSITIVE HER-2 NEGATIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New imaging tracer could spot hidden cancers
- Timing matters: menstrual cycle may influence breast cancer treatment choices
- New combo therapy aims to slow advanced breast cancer in BRCA patients
- New Triple-Drug attack shows promise for Hard-to-Treat breast cancer
- New hope for tough breast cancer: experimental drug EP0062 enters human trials
- New cancer drug candidate BG-68501 enters first human trials